Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 14, 2026

Quantitative Fluorescence In Situ Hybridization (FISH) and Immunofluorescence (IF) of Specific Gene Products in KSHV-Infected Cells
06:21

Quantitative Fluorescence In Situ Hybridization (FISH) and Immunofluorescence (IF) of Specific Gene Products in KSHV-Infected Cells

Published on: August 27, 2019

NFkappaB decoy oligonucleotides.

Daniela De Stefano1, Giuseppe De Rosa, Rosa Carnuccio

  • 1University of Naples Federico II, Department of Experimental Pharmacology, via D Montesano 49, 80131 Naples, Italy. dadestef@unina.it.

Current Opinion in Molecular Therapeutics
|April 8, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiplex Detection and Quantification of miRNAs in Drug Delivery Systems Using a Signal-Off Electrochemical Platform.

Analytical chemistry·2026
Same author

Nature Meets Science: The Role of Food-Grade Oils and Green Excipients in Pharmaceutical Nanoemulsion Formulation.

Materials (Basel, Switzerland)·2026
Same author

Lipid self-assembling nanoparticles as a novel platform for mRNA-based vaccination.

Molecular therapy. Nucleic acids·2026
Same author

Special issue: Phospholipids as functional ingredients in pharmaceutical formulations: Current advances and perspectives.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Effect of IL-1β on NSCLC-Derived Small Extracellular Vesicles as Actors in Mediating Cancer Progression and Evading Immune System.

International journal of molecular sciences·2025
Same author

Development of an Electrochemical Biosensor to Detect miRNA Encapsulated in Lipid Nanoparticles.

Analytical chemistry·2025

Decoy oligonucleotides targeting NF-kappaB show promise for inflammatory diseases. Strategies are improving their delivery and effectiveness for clinical use.

Area of Science:

  • Molecular therapy
  • Immunology
  • Pharmacology

Background:

  • Inflammatory diseases pose significant health challenges.
  • NF-kappaB is a key transcription factor in inflammatory and immune responses.
  • Decoy oligonucleotides (ONs) offer a targeted approach to inhibit NF-kappaB activity.

Purpose of the Study:

  • To review the preclinical and clinical applications of NF-kappaB decoy ONs.
  • To highlight strategies for overcoming pharmacokinetic limitations of ONs.

Main Methods:

  • Review of existing scientific literature on NF-kappaB decoy ONs.
  • Analysis of studies investigating chemical modifications and delivery systems for ONs.

Main Results:

More Related Videos

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle
10:05

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

Published on: March 5, 2019

Related Experiment Videos

Last Updated: Jun 14, 2026

Quantitative Fluorescence In Situ Hybridization (FISH) and Immunofluorescence (IF) of Specific Gene Products in KSHV-Infected Cells
06:21

Quantitative Fluorescence In Situ Hybridization (FISH) and Immunofluorescence (IF) of Specific Gene Products in KSHV-Infected Cells

Published on: August 27, 2019

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle
10:05

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

Published on: March 5, 2019

  • Decoy ONs effectively block NF-kappaB transcriptional activity.
  • Pharmacokinetic issues like low bioavailability and short half-life limit clinical use.
  • Chemical modifications and advanced delivery systems show potential to improve ON efficacy.

    • Conclusions:

    • NF-kappaB decoy ONs represent a promising molecular therapy for inflammatory diseases.
    • Overcoming pharmacokinetic challenges is crucial for successful clinical translation.
    • Further research into optimized delivery systems is warranted.